---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000100"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-08-06T11:03:44+00:00"
generated_at: "2026-08-06T11:06:34.111361+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics Q2 2026 net income $15.8M; cash $149.3M; Phase 3 AURORA data expected 1Q27

## Summary
- Net income $15.8M ($0.47 basic EPS) vs $15.9M prior year; R&D expenses $20.4M, G&A $8.7M.
- Cash $149.3M as of June 30, 2026; cash runway into 2028 via up to $150M K2HV credit facility (first $50M funded).
- Phase 3 AURORA trial of Descartes-08 in MG on track; data expected 1Q27, BLA filing mid-2027.
- Phase 2 TRITON myositis data subset expected 1H27; Phase 1/2 HELIOS pediatric JDM data expected 1H27.
- New licensing agreement with WestGene for in vivo CAR-T; Phase 1 trial 2H26 with data 1H27.

## SEC filing metadata
- accession: 0001453687-26-000100
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-08-06T11:03:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/0001453687-26-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/rnac-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000100
- JSON: https://secwatch.observer/filing/0001453687-26-000100.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.